Trivirus Specific CTLs

also known as CHM-CTLs

Developed for: adenoviridae infectious disease · Epstein-Barr virus infection · cytomegalovirus infection
Investigated by: Baylor College of Medicine · Children's Hospital Los Angeles · Duke University · Hackensack Meridian Health · The Methodist Hospital Research Institute · Beth Israel Deaconess Medical Center
+14 more
· Boston Children's Hospital · Brigham and Women's Hospital · Center for Cell and Gene Therapy, Baylor College of Medicine · Children's National Research Institute · Johns Hopkins All Children's Hospital · M.D. Anderson Cancer Center · Massachusetts General Hospital · National Heart, Lung, and Blood Institute (NHLBI) · National Marrow Donor Program · New York Medical College · The Emmes Company, LLC · University of California, Los Angeles · University of Miami · University of Texas Southwestern Medical Center

today NCT00711035 · Ph 1/2

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT00711035	Nov 2008 → Oct 2012	Epstein-Barr virus infection, adenoviridae infectious disease	Baylor College of Medicine	Completed	No outcome recorded
Phase not stated1 trial
—	NCT01945619	—	Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection	Baylor College of Medicine	No longer available	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Trivirus Specific CTLs	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00711035 ↗ 1 NCT01945619 ↗
Known as	CHM-CTLs	“This trial is designed to evaluate the feasibility, safety and efficacy of most closely HLA-matched multivirus specific CTL lines (CHM-CTLs) in HSCT patients with EBV, CMV or...” NCT00711035 ↗
Modality	Cell therapy	“The CTL line will be derived from donor peripheral blood T cells” NCT00711035 ↗
Route	Intravenous	“The cells will be thawed and injected into an intravenous line over 1-5 minutes.” NCT01945619 ↗